Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Lymphohistiocytosis, Hemophagocytic | 11 | 2023 | 260 | 3.820 |
Why?
|
Graft vs Host Disease | 39 | 2024 | 2958 | 3.460 |
Why?
|
Hematopoietic Stem Cell Transplantation | 53 | 2024 | 5445 | 3.270 |
Why?
|
Immunotherapy, Adoptive | 16 | 2024 | 1271 | 1.800 |
Why?
|
Transplantation Conditioning | 18 | 2024 | 1599 | 1.380 |
Why?
|
Cord Blood Stem Cell Transplantation | 4 | 2019 | 314 | 1.150 |
Why?
|
Hematologic Neoplasms | 15 | 2022 | 1832 | 1.140 |
Why?
|
Herpesvirus 4, Human | 8 | 2024 | 1041 | 0.820 |
Why?
|
NK Cell Lectin-Like Receptor Subfamily K | 2 | 2018 | 91 | 0.800 |
Why?
|
Myelodysplastic Syndromes | 5 | 2018 | 1352 | 0.780 |
Why?
|
Transplantation, Homologous | 20 | 2024 | 4777 | 0.770 |
Why?
|
T-Lymphocytes | 13 | 2023 | 10183 | 0.710 |
Why?
|
Interleukin-2 Receptor alpha Subunit | 2 | 2022 | 310 | 0.690 |
Why?
|
Interleukin-2 | 8 | 2022 | 1904 | 0.670 |
Why?
|
Myeloablative Agonists | 4 | 2018 | 218 | 0.670 |
Why?
|
Leukemia, Myeloid, Acute | 9 | 2024 | 3524 | 0.670 |
Why?
|
Macrophage Activation Syndrome | 1 | 2019 | 111 | 0.650 |
Why?
|
Graft vs Tumor Effect | 1 | 2016 | 72 | 0.560 |
Why?
|
Transplants | 1 | 2018 | 209 | 0.550 |
Why?
|
Graft vs Leukemia Effect | 2 | 2020 | 111 | 0.530 |
Why?
|
Fetal Blood | 3 | 2016 | 1318 | 0.530 |
Why?
|
Lymphocyte Transfusion | 1 | 2016 | 236 | 0.520 |
Why?
|
Blood Specimen Collection | 1 | 2016 | 246 | 0.520 |
Why?
|
Neurotoxicity Syndromes | 4 | 2023 | 290 | 0.510 |
Why?
|
Immunologic Deficiency Syndromes | 1 | 2018 | 547 | 0.500 |
Why?
|
Epstein-Barr Virus Infections | 5 | 2024 | 570 | 0.500 |
Why?
|
Hepatic Veno-Occlusive Disease | 3 | 2022 | 220 | 0.470 |
Why?
|
T-Lymphocytes, Regulatory | 9 | 2022 | 2988 | 0.470 |
Why?
|
Antilymphocyte Serum | 1 | 2015 | 492 | 0.450 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2018 | 689 | 0.450 |
Why?
|
Viral Matrix Proteins | 1 | 2014 | 186 | 0.440 |
Why?
|
Lymphoma | 4 | 2020 | 1877 | 0.430 |
Why?
|
Hematopoietic Stem Cells | 5 | 2022 | 3390 | 0.430 |
Why?
|
Cytokines | 6 | 2024 | 7323 | 0.420 |
Why?
|
Recurrence | 15 | 2023 | 8340 | 0.390 |
Why?
|
Antigens, CD19 | 4 | 2022 | 380 | 0.390 |
Why?
|
Tissue Donors | 5 | 2022 | 2241 | 0.380 |
Why?
|
Receptors, Antigen, T-Cell | 8 | 2024 | 2540 | 0.370 |
Why?
|
Gastrointestinal Diseases | 1 | 2018 | 1170 | 0.350 |
Why?
|
Pyrazoles | 2 | 2019 | 1972 | 0.350 |
Why?
|
Blood Component Removal | 2 | 2022 | 125 | 0.350 |
Why?
|
Virus Diseases | 1 | 2015 | 711 | 0.330 |
Why?
|
Lymphoproliferative Disorders | 2 | 2024 | 524 | 0.320 |
Why?
|
Humans | 111 | 2024 | 744366 | 0.320 |
Why?
|
Antiphospholipid Syndrome | 1 | 2010 | 173 | 0.320 |
Why?
|
Epstein-Barr Virus Nuclear Antigens | 3 | 2003 | 150 | 0.320 |
Why?
|
Ferritins | 3 | 2022 | 590 | 0.310 |
Why?
|
Lymphoma, Non-Hodgkin | 3 | 2020 | 1381 | 0.310 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 3 | 2022 | 1378 | 0.300 |
Why?
|
Adult | 57 | 2023 | 214052 | 0.300 |
Why?
|
CD4-Positive T-Lymphocytes | 7 | 2020 | 4386 | 0.290 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2014 | 1821 | 0.280 |
Why?
|
Steroids | 6 | 2023 | 930 | 0.280 |
Why?
|
Multiple Myeloma | 2 | 2023 | 5181 | 0.250 |
Why?
|
Dioxygenases | 3 | 2021 | 316 | 0.250 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 3 | 2021 | 1596 | 0.250 |
Why?
|
Killer Cells, Natural | 6 | 2022 | 2133 | 0.250 |
Why?
|
CD8-Positive T-Lymphocytes | 9 | 2024 | 4479 | 0.250 |
Why?
|
Cyclophosphamide | 6 | 2023 | 2242 | 0.240 |
Why?
|
Transplantation Chimera | 3 | 2015 | 613 | 0.230 |
Why?
|
Hematopoietic Stem Cell Mobilization | 3 | 2022 | 227 | 0.230 |
Why?
|
Activated-Leukocyte Cell Adhesion Molecule | 1 | 2022 | 22 | 0.220 |
Why?
|
Cytotoxicity, Immunologic | 2 | 2003 | 1369 | 0.220 |
Why?
|
Perforin | 2 | 2018 | 168 | 0.210 |
Why?
|
Aged | 38 | 2022 | 163288 | 0.210 |
Why?
|
Middle Aged | 43 | 2022 | 213390 | 0.200 |
Why?
|
Transplantation, Autologous | 4 | 2021 | 2124 | 0.200 |
Why?
|
Autoantibodies | 1 | 2010 | 2036 | 0.200 |
Why?
|
Anemia, Sickle Cell | 2 | 2020 | 1020 | 0.200 |
Why?
|
B-Lymphocytes | 4 | 2004 | 4666 | 0.200 |
Why?
|
Ligands | 2 | 2018 | 3282 | 0.200 |
Why?
|
Clone Cells | 4 | 2020 | 1692 | 0.190 |
Why?
|
Natural Killer T-Cells | 1 | 2024 | 316 | 0.190 |
Why?
|
Opportunistic Infections | 1 | 2023 | 389 | 0.190 |
Why?
|
Male | 45 | 2024 | 350115 | 0.180 |
Why?
|
gamma-Globins | 1 | 2020 | 95 | 0.180 |
Why?
|
Survival Rate | 9 | 2022 | 12788 | 0.180 |
Why?
|
Janus Kinase 1 | 1 | 2019 | 104 | 0.170 |
Why?
|
Certification | 1 | 2023 | 423 | 0.170 |
Why?
|
Photopheresis | 1 | 2019 | 24 | 0.170 |
Why?
|
BK Virus | 1 | 2020 | 129 | 0.170 |
Why?
|
Receptors, Interleukin-6 | 1 | 2020 | 225 | 0.170 |
Why?
|
Female | 45 | 2024 | 380193 | 0.170 |
Why?
|
Disease-Free Survival | 6 | 2018 | 6896 | 0.160 |
Why?
|
Biological Products | 3 | 2022 | 860 | 0.160 |
Why?
|
Interleukin 1 Receptor Antagonist Protein | 1 | 2019 | 297 | 0.160 |
Why?
|
Bone Marrow Transplantation | 2 | 2023 | 2765 | 0.160 |
Why?
|
Fetal Hemoglobin | 1 | 2020 | 341 | 0.160 |
Why?
|
Peripheral Blood Stem Cell Transplantation | 2 | 2018 | 272 | 0.160 |
Why?
|
Lymphocyte Activation | 4 | 2022 | 5524 | 0.150 |
Why?
|
Chronic Disease | 11 | 2023 | 9145 | 0.150 |
Why?
|
Gene Expression Regulation, Leukemic | 1 | 2021 | 651 | 0.150 |
Why?
|
Vidarabine | 4 | 2021 | 345 | 0.150 |
Why?
|
Heterocyclic Compounds | 1 | 2018 | 249 | 0.150 |
Why?
|
Young Adult | 18 | 2021 | 56429 | 0.150 |
Why?
|
Sulfonamides | 2 | 2024 | 1940 | 0.150 |
Why?
|
Cytomegalovirus Infections | 1 | 2023 | 820 | 0.150 |
Why?
|
Clinical Trials as Topic | 4 | 2021 | 7914 | 0.140 |
Why?
|
Hematologic Diseases | 2 | 2018 | 498 | 0.140 |
Why?
|
Janus Kinase 2 | 1 | 2019 | 528 | 0.140 |
Why?
|
Cryopreservation | 2 | 2021 | 670 | 0.140 |
Why?
|
Tacrolimus | 4 | 2023 | 743 | 0.140 |
Why?
|
Tandem Repeat Sequences | 1 | 2016 | 185 | 0.130 |
Why?
|
Retrospective Studies | 20 | 2023 | 77460 | 0.130 |
Why?
|
Down-Regulation | 2 | 2020 | 3001 | 0.130 |
Why?
|
Stem Cell Factor | 1 | 2015 | 219 | 0.130 |
Why?
|
Interleukin-7 | 1 | 2015 | 142 | 0.130 |
Why?
|
Kidney | 2 | 2010 | 7184 | 0.120 |
Why?
|
Mediastinal Neoplasms | 1 | 2017 | 423 | 0.120 |
Why?
|
Cell Division | 2 | 2004 | 4569 | 0.120 |
Why?
|
T-Lymphocyte Subsets | 3 | 2016 | 1837 | 0.120 |
Why?
|
Nitriles | 1 | 2019 | 955 | 0.120 |
Why?
|
Lymphocyte Depletion | 1 | 2016 | 608 | 0.120 |
Why?
|
Niacinamide | 1 | 2016 | 416 | 0.120 |
Why?
|
Brain Edema | 1 | 2018 | 617 | 0.120 |
Why?
|
HLA Antigens | 1 | 2019 | 1382 | 0.120 |
Why?
|
Busulfan | 3 | 2021 | 263 | 0.120 |
Why?
|
Consensus | 1 | 2023 | 2960 | 0.110 |
Why?
|
Organ Transplantation | 1 | 2024 | 1140 | 0.110 |
Why?
|
Combined Modality Therapy | 3 | 2024 | 8642 | 0.110 |
Why?
|
Remission Induction | 2 | 2016 | 2385 | 0.110 |
Why?
|
Receptors, Interleukin-2 | 1 | 2015 | 573 | 0.110 |
Why?
|
Antigens, Surface | 1 | 2017 | 1663 | 0.110 |
Why?
|
Phenylurea Compounds | 1 | 2016 | 528 | 0.110 |
Why?
|
Drug Resistance | 1 | 2019 | 1608 | 0.110 |
Why?
|
fms-Like Tyrosine Kinase 3 | 1 | 2016 | 491 | 0.110 |
Why?
|
DNA-Binding Proteins | 4 | 2021 | 9647 | 0.110 |
Why?
|
Lymphocyte Count | 3 | 2019 | 793 | 0.110 |
Why?
|
Histocompatibility Testing | 3 | 2015 | 741 | 0.110 |
Why?
|
Child | 8 | 2023 | 77709 | 0.100 |
Why?
|
Models, Immunological | 1 | 2014 | 527 | 0.100 |
Why?
|
Treatment Outcome | 11 | 2021 | 63107 | 0.100 |
Why?
|
Repressor Proteins | 2 | 2020 | 3024 | 0.100 |
Why?
|
RNA Interference | 1 | 2020 | 2890 | 0.100 |
Why?
|
Incidence | 4 | 2023 | 20952 | 0.100 |
Why?
|
Neoplasm, Residual | 1 | 2016 | 973 | 0.100 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2020 | 1520 | 0.100 |
Why?
|
Gene Deletion | 1 | 2019 | 2751 | 0.100 |
Why?
|
Mutation | 6 | 2021 | 29786 | 0.100 |
Why?
|
DNA, Neoplasm | 1 | 2016 | 1758 | 0.100 |
Why?
|
Saccharomyces cerevisiae | 1 | 2022 | 2751 | 0.100 |
Why?
|
Lymphoma, B-Cell | 1 | 2017 | 931 | 0.100 |
Why?
|
Cell Proliferation | 4 | 2019 | 10483 | 0.100 |
Why?
|
Cell Separation | 1 | 2016 | 1751 | 0.090 |
Why?
|
Prognosis | 6 | 2022 | 29060 | 0.090 |
Why?
|
Phagocytosis | 2 | 2015 | 1539 | 0.090 |
Why?
|
Receptors, IgE | 2 | 2003 | 389 | 0.090 |
Why?
|
Cytomegalovirus | 1 | 2015 | 733 | 0.090 |
Why?
|
Stilbenes | 1 | 2011 | 155 | 0.090 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2014 | 627 | 0.090 |
Why?
|
T-Lymphocytes, Helper-Inducer | 1 | 2016 | 985 | 0.090 |
Why?
|
Acute Kidney Injury | 1 | 2023 | 1968 | 0.090 |
Why?
|
Herpesvirus 8, Human | 2 | 2004 | 258 | 0.090 |
Why?
|
Boronic Acids | 1 | 2014 | 965 | 0.090 |
Why?
|
Alleles | 4 | 2024 | 6933 | 0.090 |
Why?
|
Hematopoiesis | 2 | 2017 | 2073 | 0.090 |
Why?
|
Prednisone | 1 | 2014 | 1574 | 0.090 |
Why?
|
Plasmapheresis | 1 | 2010 | 211 | 0.090 |
Why?
|
Tumor Necrosis Factor-alpha | 2 | 2011 | 4424 | 0.090 |
Why?
|
Phenotype | 2 | 2018 | 16367 | 0.080 |
Why?
|
Hodgkin Disease | 1 | 2017 | 1415 | 0.080 |
Why?
|
Leukocytes, Mononuclear | 1 | 2016 | 1837 | 0.080 |
Why?
|
Neoplasms, Second Primary | 1 | 2017 | 1062 | 0.080 |
Why?
|
Stem Cell Transplantation | 1 | 2017 | 1620 | 0.080 |
Why?
|
Glioblastoma | 1 | 2024 | 3481 | 0.080 |
Why?
|
Neoplasm Proteins | 1 | 2021 | 3707 | 0.080 |
Why?
|
Cardiomyopathies | 1 | 2020 | 1912 | 0.080 |
Why?
|
Epitopes | 1 | 2015 | 2571 | 0.080 |
Why?
|
Cells, Cultured | 4 | 2016 | 19233 | 0.080 |
Why?
|
Pyrazines | 1 | 2014 | 1230 | 0.080 |
Why?
|
Adolescent | 12 | 2021 | 85779 | 0.080 |
Why?
|
Whole-Body Irradiation | 2 | 2019 | 449 | 0.080 |
Why?
|
Molecular Targeted Therapy | 1 | 2019 | 2725 | 0.080 |
Why?
|
United States | 7 | 2024 | 69872 | 0.080 |
Why?
|
Polymorphism, Single Nucleotide | 3 | 2019 | 15520 | 0.080 |
Why?
|
Protein Kinase Inhibitors | 2 | 2016 | 5534 | 0.080 |
Why?
|
Pyrimidines | 1 | 2019 | 2943 | 0.070 |
Why?
|
Erythropoiesis | 1 | 2011 | 706 | 0.070 |
Why?
|
Erythrocytes | 1 | 2016 | 2455 | 0.070 |
Why?
|
Survival Analysis | 5 | 2018 | 10252 | 0.070 |
Why?
|
Immunotherapy | 2 | 2019 | 4446 | 0.070 |
Why?
|
Cell Line, Tumor | 4 | 2018 | 16690 | 0.070 |
Why?
|
Fas Ligand Protein | 2 | 2003 | 216 | 0.070 |
Why?
|
Melanoma | 1 | 2024 | 5511 | 0.070 |
Why?
|
Lymphocytes | 2 | 2024 | 2617 | 0.060 |
Why?
|
Neutropenia | 1 | 2010 | 895 | 0.060 |
Why?
|
Polyglutamic Acid | 2 | 1994 | 44 | 0.060 |
Why?
|
Disease Management | 1 | 2015 | 2460 | 0.060 |
Why?
|
Venous Thromboembolism | 1 | 2017 | 1671 | 0.060 |
Why?
|
Treatment Failure | 2 | 2020 | 2618 | 0.060 |
Why?
|
Neutrophils | 1 | 2016 | 3721 | 0.060 |
Why?
|
Trans-Activators | 2 | 2007 | 2926 | 0.060 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2011 | 1660 | 0.060 |
Why?
|
Pore Forming Cytotoxic Proteins | 1 | 2003 | 130 | 0.060 |
Why?
|
Aged, 80 and over | 5 | 2020 | 57776 | 0.060 |
Why?
|
Neoplasms | 2 | 2024 | 21696 | 0.060 |
Why?
|
Societies | 1 | 2023 | 104 | 0.060 |
Why?
|
Immunoglobulin A | 1 | 2007 | 995 | 0.060 |
Why?
|
RNA, Transfer, Lys | 1 | 2002 | 9 | 0.050 |
Why?
|
Antigens, Viral | 1 | 2007 | 1035 | 0.050 |
Why?
|
NF-kappa B | 1 | 2011 | 2499 | 0.050 |
Why?
|
Fetal Proteins | 1 | 2022 | 94 | 0.050 |
Why?
|
Immunophenotyping | 2 | 2018 | 1880 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3135 | 0.050 |
Why?
|
Azacitidine | 1 | 2024 | 347 | 0.050 |
Why?
|
Cell Transformation, Viral | 1 | 2003 | 567 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3242 | 0.050 |
Why?
|
Immunologic Memory | 2 | 2016 | 1348 | 0.050 |
Why?
|
Age Factors | 2 | 2015 | 18373 | 0.050 |
Why?
|
Antigens, CD34 | 2 | 2016 | 659 | 0.050 |
Why?
|
Serology | 1 | 2001 | 7 | 0.050 |
Why?
|
HIV Reverse Transcriptase | 1 | 2002 | 213 | 0.050 |
Why?
|
Graft Rejection | 1 | 2014 | 4397 | 0.050 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2011 | 2282 | 0.050 |
Why?
|
Cell Adhesion Molecules, Neuronal | 1 | 2022 | 266 | 0.050 |
Why?
|
Polydeoxyribonucleotides | 1 | 2022 | 127 | 0.050 |
Why?
|
Anemia | 1 | 2010 | 1503 | 0.050 |
Why?
|
Intubation | 1 | 2020 | 141 | 0.050 |
Why?
|
Antigens, Differentiation, T-Lymphocyte | 1 | 2022 | 906 | 0.050 |
Why?
|
Burkitt Lymphoma | 1 | 2002 | 327 | 0.050 |
Why?
|
Respiratory Therapy | 1 | 2020 | 132 | 0.040 |
Why?
|
Signal Transduction | 3 | 2019 | 23404 | 0.040 |
Why?
|
Methotrexate | 2 | 2018 | 1728 | 0.040 |
Why?
|
Kaplan-Meier Estimate | 2 | 2021 | 6539 | 0.040 |
Why?
|
Toll-Like Receptor 9 | 1 | 2020 | 212 | 0.040 |
Why?
|
Viral Proteins | 1 | 2007 | 1900 | 0.040 |
Why?
|
Histocompatibility Antigens Class II | 1 | 2003 | 1475 | 0.040 |
Why?
|
Cell Size | 1 | 2001 | 643 | 0.040 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2022 | 903 | 0.040 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2024 | 1038 | 0.040 |
Why?
|
Gene Expression Regulation, Viral | 1 | 2000 | 442 | 0.040 |
Why?
|
Leukemia, Myeloid | 1 | 2021 | 707 | 0.040 |
Why?
|
Risk Factors | 4 | 2020 | 72296 | 0.040 |
Why?
|
Biopsy | 1 | 2010 | 6755 | 0.040 |
Why?
|
Melphalan | 1 | 2019 | 431 | 0.040 |
Why?
|
Amino Acid Substitution | 2 | 2018 | 1793 | 0.040 |
Why?
|
Benzylamines | 1 | 2018 | 223 | 0.040 |
Why?
|
Acute Disease | 2 | 2020 | 7147 | 0.040 |
Why?
|
Immediate-Early Proteins | 1 | 2000 | 453 | 0.040 |
Why?
|
Mice, Mutant Strains | 1 | 2020 | 1865 | 0.040 |
Why?
|
Th1 Cells | 1 | 2002 | 1057 | 0.040 |
Why?
|
Coculture Techniques | 2 | 2016 | 1341 | 0.040 |
Why?
|
Maximum Tolerated Dose | 1 | 2019 | 892 | 0.040 |
Why?
|
Cell Line | 4 | 2004 | 16000 | 0.040 |
Why?
|
Time Factors | 4 | 2021 | 40075 | 0.040 |
Why?
|
Simian immunodeficiency virus | 1 | 2002 | 846 | 0.040 |
Why?
|
Leukopenia | 1 | 2017 | 213 | 0.040 |
Why?
|
Pilot Projects | 2 | 2020 | 8319 | 0.040 |
Why?
|
Lymphocyte Cooperation | 1 | 2016 | 112 | 0.030 |
Why?
|
Proto-Oncogene Proteins | 2 | 2020 | 4554 | 0.030 |
Why?
|
Workflow | 1 | 2021 | 847 | 0.030 |
Why?
|
STAT5 Transcription Factor | 1 | 2016 | 259 | 0.030 |
Why?
|
Germ Cells | 1 | 2020 | 631 | 0.030 |
Why?
|
Antineoplastic Agents | 2 | 2016 | 13693 | 0.030 |
Why?
|
Gene Knockdown Techniques | 1 | 2020 | 1656 | 0.030 |
Why?
|
Outpatients | 1 | 2023 | 1487 | 0.030 |
Why?
|
Follow-Up Studies | 4 | 2022 | 39052 | 0.030 |
Why?
|
Antibodies, Viral | 1 | 2007 | 3177 | 0.030 |
Why?
|
Membrane Glycoproteins | 2 | 2003 | 3771 | 0.030 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2024 | 9240 | 0.030 |
Why?
|
Genetic Predisposition to Disease | 2 | 2015 | 17446 | 0.030 |
Why?
|
Sequence Analysis, DNA | 2 | 2017 | 4805 | 0.030 |
Why?
|
Lymphopoiesis | 1 | 2016 | 135 | 0.030 |
Why?
|
Graft Survival | 2 | 2017 | 3737 | 0.030 |
Why?
|
Immunoprecipitation | 1 | 2017 | 906 | 0.030 |
Why?
|
Inflammation | 1 | 2015 | 10637 | 0.030 |
Why?
|
Algorithms | 1 | 2015 | 13882 | 0.030 |
Why?
|
Flow Cytometry | 2 | 2007 | 5974 | 0.030 |
Why?
|
Anticoagulants | 1 | 2010 | 4600 | 0.030 |
Why?
|
Platelet Count | 1 | 2017 | 780 | 0.030 |
Why?
|
Gastrointestinal Tract | 1 | 2020 | 814 | 0.030 |
Why?
|
Anti-Inflammatory Agents | 1 | 2024 | 1790 | 0.030 |
Why?
|
Virus Replication | 1 | 2002 | 2535 | 0.030 |
Why?
|
Interleukin-6 | 1 | 2004 | 3203 | 0.030 |
Why?
|
Age of Onset | 1 | 2020 | 3270 | 0.030 |
Why?
|
Fatal Outcome | 1 | 2018 | 1851 | 0.030 |
Why?
|
Chemoembolization, Therapeutic | 1 | 1994 | 129 | 0.030 |
Why?
|
Leukemia | 1 | 2021 | 1510 | 0.030 |
Why?
|
Immunoglobulins | 1 | 2016 | 881 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2018 | 10943 | 0.030 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2016 | 648 | 0.030 |
Why?
|
Antibody Formation | 1 | 2017 | 1402 | 0.030 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2011 | 5223 | 0.030 |
Why?
|
Dendritic Cells | 1 | 2003 | 2725 | 0.030 |
Why?
|
Plasma Cells | 1 | 2016 | 591 | 0.030 |
Why?
|
Animals | 4 | 2020 | 168768 | 0.030 |
Why?
|
RNA | 1 | 2002 | 2749 | 0.030 |
Why?
|
Syndrome | 1 | 2018 | 3252 | 0.030 |
Why?
|
Disease Progression | 2 | 2020 | 13286 | 0.030 |
Why?
|
Antigens, CD | 1 | 2022 | 4026 | 0.030 |
Why?
|
Death | 1 | 2016 | 678 | 0.030 |
Why?
|
Erythroid-Specific DNA-Binding Factors | 1 | 2011 | 198 | 0.030 |
Why?
|
Cell Count | 1 | 2016 | 1856 | 0.030 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2021 | 2943 | 0.020 |
Why?
|
Disease Susceptibility | 1 | 2018 | 1782 | 0.020 |
Why?
|
Adrenal Cortex Hormones | 1 | 2020 | 1856 | 0.020 |
Why?
|
RNA, Small Interfering | 1 | 2020 | 3505 | 0.020 |
Why?
|
Breast Neoplasms | 1 | 2018 | 20824 | 0.020 |
Why?
|
Genetic Vectors | 1 | 2020 | 3424 | 0.020 |
Why?
|
Skin Diseases | 1 | 2019 | 1066 | 0.020 |
Why?
|
Pandemics | 2 | 2021 | 8385 | 0.020 |
Why?
|
Erythroid Precursor Cells | 1 | 2011 | 218 | 0.020 |
Why?
|
Genetic Markers | 1 | 2017 | 2634 | 0.020 |
Why?
|
Mass Spectrometry | 1 | 2017 | 2204 | 0.020 |
Why?
|
Immune Tolerance | 1 | 2019 | 2259 | 0.020 |
Why?
|
Vaccination | 1 | 2022 | 3279 | 0.020 |
Why?
|
Th17 Cells | 1 | 2016 | 766 | 0.020 |
Why?
|
Antibodies | 1 | 2017 | 2460 | 0.020 |
Why?
|
Lung Diseases | 1 | 2019 | 1887 | 0.020 |
Why?
|
C-Reactive Protein | 1 | 2020 | 3778 | 0.020 |
Why?
|
Cisplatin | 1 | 1994 | 1662 | 0.020 |
Why?
|
Patient Selection | 1 | 2020 | 4216 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2017 | 4185 | 0.020 |
Why?
|
Prospective Studies | 3 | 2020 | 53290 | 0.020 |
Why?
|
Cohort Studies | 3 | 2018 | 40559 | 0.020 |
Why?
|
Boston | 1 | 2020 | 9312 | 0.020 |
Why?
|
Kinetics | 1 | 2015 | 6476 | 0.020 |
Why?
|
Lung Neoplasms | 1 | 2011 | 13104 | 0.020 |
Why?
|
Cell Nucleus | 1 | 2016 | 2969 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2020 | 12025 | 0.020 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2017 | 2949 | 0.020 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2011 | 1375 | 0.020 |
Why?
|
Immunosuppressive Agents | 1 | 2018 | 4153 | 0.020 |
Why?
|
Antibodies, Monoclonal | 1 | 2022 | 9274 | 0.020 |
Why?
|
Contactins | 1 | 2004 | 21 | 0.020 |
Why?
|
HIV-1 | 1 | 2002 | 6939 | 0.020 |
Why?
|
Survivors | 1 | 2014 | 2291 | 0.010 |
Why?
|
Neural Cell Adhesion Molecules | 1 | 2004 | 126 | 0.010 |
Why?
|
Genetic Variation | 1 | 2019 | 6542 | 0.010 |
Why?
|
Child, Preschool | 2 | 2021 | 41005 | 0.010 |
Why?
|
Binding Sites | 2 | 2002 | 6111 | 0.010 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2011 | 1581 | 0.010 |
Why?
|
Gene Expression | 1 | 2016 | 7798 | 0.010 |
Why?
|
Cytopathogenic Effect, Viral | 1 | 2002 | 156 | 0.010 |
Why?
|
HLA-DQ Antigens | 1 | 2002 | 210 | 0.010 |
Why?
|
Viral Core Proteins | 1 | 2002 | 162 | 0.010 |
Why?
|
Gene Products, gag | 1 | 2002 | 337 | 0.010 |
Why?
|
Base Sequence | 2 | 2003 | 12797 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2015 | 12244 | 0.010 |
Why?
|
Models, Molecular | 1 | 2011 | 5451 | 0.010 |
Why?
|
Phosphonoacetic Acid | 1 | 2000 | 55 | 0.010 |
Why?
|
Glycosylation | 1 | 2004 | 1128 | 0.010 |
Why?
|
Contrast Media | 1 | 1994 | 5300 | 0.010 |
Why?
|
HLA-DR Antigens | 1 | 2002 | 645 | 0.010 |
Why?
|
Particle Size | 2 | 1994 | 1642 | 0.010 |
Why?
|
Infant | 1 | 2021 | 35134 | 0.010 |
Why?
|
Pyridines | 1 | 2011 | 2825 | 0.010 |
Why?
|
Nucleotides | 1 | 2002 | 464 | 0.010 |
Why?
|
DNA Primers | 1 | 2003 | 2891 | 0.010 |
Why?
|
Deoxyribonucleases | 1 | 2000 | 214 | 0.010 |
Why?
|
Nucleic Acid Conformation | 1 | 2002 | 913 | 0.010 |
Why?
|
Plasmids | 1 | 2004 | 2308 | 0.010 |
Why?
|
Epitopes, T-Lymphocyte | 1 | 2002 | 880 | 0.010 |
Why?
|
Cloning, Molecular | 1 | 2004 | 4320 | 0.010 |
Why?
|
Recombination, Genetic | 1 | 2002 | 1586 | 0.010 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 11525 | 0.010 |
Why?
|
Reverse Transcriptase Inhibitors | 1 | 2000 | 615 | 0.010 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2011 | 5172 | 0.010 |
Why?
|
Risk Assessment | 1 | 2017 | 23336 | 0.010 |
Why?
|
Iopanoic Acid | 1 | 1994 | 20 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 2004 | 6621 | 0.010 |
Why?
|
Mice | 1 | 2020 | 81201 | 0.010 |
Why?
|
Capsules | 1 | 1994 | 196 | 0.010 |
Why?
|
DNA, Viral | 1 | 2000 | 2227 | 0.010 |
Why?
|
Estrone | 1 | 1994 | 240 | 0.010 |
Why?
|
Enzymes | 1 | 1994 | 266 | 0.010 |
Why?
|
Tumor Cells, Cultured | 1 | 2000 | 6313 | 0.010 |
Why?
|
Microspheres | 1 | 1994 | 777 | 0.010 |
Why?
|
Escherichia coli | 1 | 2004 | 4217 | 0.010 |
Why?
|
Peptide Fragments | 1 | 2004 | 5096 | 0.010 |
Why?
|
Tissue Distribution | 1 | 1994 | 2327 | 0.010 |
Why?
|
Drug Carriers | 1 | 1994 | 693 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 2002 | 18111 | 0.010 |
Why?
|
Rabbits | 1 | 1994 | 4894 | 0.000 |
Why?
|
Receptors, Estrogen | 1 | 1994 | 2190 | 0.000 |
Why?
|
RNA, Messenger | 1 | 2000 | 13035 | 0.000 |
Why?
|
Swine | 1 | 1994 | 5918 | 0.000 |
Why?
|
Liver | 1 | 1994 | 7475 | 0.000 |
Why?
|
Rats | 1 | 1994 | 24252 | 0.000 |
Why?
|
Tomography, X-Ray Computed | 1 | 1994 | 20130 | 0.000 |
Why?
|